Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy
- Conditions
- Cervical Spondylotic Myelopathy
- Interventions
- Drug: Shenqi Sherong PillDrug: Placebo
- Registration Number
- NCT06377072
- Lead Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Shenqi Sherong Pill in participants with Mild or Moderate Cervical Spondylotic Myelopathy (qi deficiency, blood stasis and kidney deficiency type) which based on placebo-control, providing a basis for drug registration.
- Detailed Description
1. Trial Design： This is a multi-center, randomized, double-blind, placebo-controlled phase III study，which plans to enroll 428 participants who will be randomized to Shenqi Sherong pill group or placebo control group. The Modified Japanese Orthopaedic Association (mJOA) Score combined with the changes of clinical symptoms and syndrome score are used as the validity index. The laboratory examination and incidence of adverse events are used as the safety index.
2. Therapeutic schedule： Participants will be provided with neck braces and recommended to wear them daily or outdoors along with health education. Participants will be treated with the investigational drug (Shenqi Sherong Pill or placebo ) by taking two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks, with a 2-week follow-up after withdrawal.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 428
Participants can only be selected if they meet all the inclusion criteria
- Age 18-75 years old (including 18 and 75 years old), gender unlimited;
- Accord with Western medicine diagnosis standards of Cervical Spondylotic Myelopathy;
- Accord with Chinese medicine diagnosis standards of qi deficiency, blood stasis and kidney deficiency type;
- The disease classification was mild or moderate (13 ≤mJOA score ≤15);
- X-ray examination of six cervical vertebrae (frontal, lateral, hyperextension and flexion lateral and double oblique) indicates cervical degenerative changes, while MRI examination indicates spinal cord compression;
- The first diagnosis of Cervical Spondylotic Myelopathy within 3 months; for those diagnosed for more than 3 months, the investigator needs to determine that the condition is basically stable;
- Participants voluntarily participate in this experiment and sign an informed consent.
Note: 1) CT examination is determined by the investigator according to the specific conditions of participants. 2) Imaging materials of MRI, X-ray(frontal, lateral, hyperextension and flexion and double oblique), CT examination within 3 months from the 3A Grade hospital can be accepted ; 3) If the laboratory tests and 12-lead electrocardiogram are completed in the research center on the same day before the participant signing an informed consent, the examination can not be repeated after the investigator judging.
Participants should be excluded if they meet any one exclusion criteria :
- The use of long-acting hormone drugs within 1 week before screening, or the last drug use is less than 7 half-lives, or Traditional Chinese Medicine, drugs with no marked half-life, physical therapy, etc. is less than 3 days before screening for the treatment of this disease;
- Participants with obvious concurrent syndrome or complication (such as Hypertension after taking antihypertensive drugs who systolic pressure ≥160mmHg, or diastolic pressure ≥100mmHg , or Diabetes after taking antidiabetic drugs who fasting blood glucose ≥10.0mmol/L and so on);
- MRI examination shows the degree of spinal stenosis is 1/2 or more, or the spinal cord compression caused by cervical spondylosis is three or more segments;
- Participants with severe hand muscle atrophy, or spasms, or is difficult to walk independently, or urinary dysfunction;
- Participants with cervical spine fracture, or congenital deformity of cervical spine, or ossification of ligamentum flavum, or ossification of posterior longitudinal ligament, or with neurological diseases such as lateral sclerosis and multiple sclerosis;
- Participants with visual analogue scale(VAS) score >7 points (7 points is defined as the distance between the left end and the mark location equal to 7.0cm);
- Participants with severe heart disease, such as myocardial infarction, unstable angina pectoris, Ⅲ to Ⅳ congestive heart failure and severe arrhythmia according to New York Heart Association (NYHA),or with severe liver and kidney diseases, or with abnormal liver and kidney function tests (Alanine aminotransferase or Aspartate aminotransferase ≥ 1.5 times the upper limit of normal, or creatinine clearance> the upper limit of normal); or with severe lung disease such as chronic bronchitis, asthma, chronic obstructive pulmonary disease(COPD) and other acute episodes;
- Participants with cerebral infarction and serious mental disorders;
- Woman in lactation, pregnancy, or planned pregnancy;
- Participant is allergic constitution or known to be allergic to the components of the investigational drug;
- Participants have participated or are participating in other clinical trials within 3 months;
- Participants are judged unsuitable for participation by the investigators in the study.
Note: 1) If examination or efficacy index score of visit 1 and visit 2 is overlapping item, the baseline standard is based on visit 2; 2) Participant who has the abnormal laboratory examination items during screening can be arranged for retest, whether to be enrolled or not will be comprehensively evaluated by the investigators.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Shenqi Sherong Pill Shenqi Sherong Pill 6g per bag Placebo Placebo 6g per bag
- Primary Outcome Measures
Name Time Method Change in Modified Japanese Orthopaedic Association (mJOA) score 42±2 days Change in Modified Japanese Orthopaedic Association (mJOA) score (on a scale from 0 to 18, with lower scores indicating greater disability) from baseline at Day 42 after administration; the mJOA which is a clinician administered scale to evaluate four clinical dimensions; motor dysfunction score for upper and lower extremities, sensation loss and sphincter dysfunction.
- Secondary Outcome Measures
Name Time Method Change in mJOA score 14±2 days, 28±2 days, 56±2 days Changes in mJOA score (on a scale from 0 to 18, with lower scores indicating greater disability) from baseline at Day 14，Day 28 and Day 56 after administration
Change in numbness (or pain) scores from the chest to the toes 14±2 days, 28±2 days, 42±2 days or 56±2 days Changes from baseline in numbness (or pain) scores (on a scale from 0 to10, with higher scores indicating greater numbness or pain) from the chest to the toes at Day 14, Day 28, Day 42 and Day 56 after administration
Change in Motor dysfunction of the upper extremities of mJOA score 14±2 days, 28±2 days, 42±2 days or 56±2 days Change in Motor dysfunction of the upper extremities of mJOA score (on a scale from 0 to 5, with lower scores indicating greater disability) at Day 14, Day 28, Day 42 and Day 56 after administration
Change in sensation of mJOA score 14±2 days, 28±2 days, 42±2 days or 56±2 days Changes in sensation of mJOA score (on a scale from 0 to 3, with lower scores indicating greater disability) from baseline at Day 14, Day 28, Day 42 and Day 56 after administration
Changes in pain or stiffness score for neck and shoulder 14±2 days, 28±2 days, 42±2 days or 56±2 days Changes in pain or stiffness score (on a scale from 0 to10, with higher scores indicating greater pain) for neck and shoulder from baseline at Day 14, Day 28, Day 42 and Day 56 after administration
Change in chest tightness score 14±2 days, 28±2 days, 42±2 days or 56±2 days Change in chest tightness score (on a scale from 0 to10, with higher scores indicating greater tightness) from baseline at Day 14, Day 28, Day 42 and Day 56 after administration
Changes in hand and arm numbness scores 14±2 days, 28±2 days, 42±2 days or 56±2 days Changes in hand and arm numbness scores (on a scale from 0 to10, with higher scores indicating greater numbness) at Day 14, Day 28, Day 42 and Day 56 after administration
Change in Traditional Chinese medicine (TCM) syndrome integrality 14±2 days, 28±2 days, 42±2 days or 56±2 days Change in Traditional Chinese medicine (TCM) syndrome integrality (on a scale from 0 to 9, with higher scores indicating greater seriousness) at Day 14, Day 28, Day 42 and Day 56 after administration
Proportion of participants with at least 1 grade decline in Nurick grades 14±2 days, 28±2 days, 42±2 days or 56±2 days Proportion of participants with at least 1 grade decline from baseline in Nurick grades (on a scale from 0 to 5, with higher scores indicating greater disability) at Day 14, Day 28, Day 42 and Day 56 after administration
Change in TCM syndrome score 14±2 days, 28±2 days, 42±2 days or 56±2 days Change in TCM syndrome score (on a scale from 0 to 9, with higher scores indicating greater seriousness) at Day 14, Day 28, Day 42 and Day 56 after administration
Trial Locations
- Locations (1)
Guangdong Provincial Hospital of Chinese Medicine
🇨🇳Guangzhou, Guangdong, China